Literature DB >> 24300584

Risk factors for inpatient venous thromboembolism despite thromboprophylaxis.

Tzu-Fei Wang1, Catherine A Wong2, Paul E Milligan3, Mark S Thoelke4, Keith F Woeltje3, Brian F Gage5.   

Abstract

INTRODUCTION: Venous thromboembolism (VTE) is the most common preventable cause of morbidity and mortality in the hospital. Adequate thromboprophylaxis has reduced the rate of hospital-acquired VTE substantially; however, some inpatients still develop VTE even when they are prescribed thromboprophylaxis. Predictors associated with thromboprophylaxis failure are unclear. In this study, we aimed to identify risk factors for inpatient VTE despite thromboprophylaxis.
MATERIALS AND METHODS: We conducted a case-control study to identify independent predictors for inpatient VTE. Among patients discharged from the BJC HealthCare system between January 2010 and May 2011, we matched 94 cases who developed in-hospital VTE while taking thromboprophylaxis to 272 controls who did not develop VTE. Matching was done by hospital, patient age, month and year of discharge. We used multivariate conditional logistic regression to develop a VTE prediction model.
RESULTS: We identified five independent risk factors for in-hospital VTE despite thromboprophylaxis: hospitalization for cranial surgery, intensive care unit admission, admission leukocyte count >13,000/mm(3), presence of an indwelling central venous catheter, and admission from a long-term care facility.
CONCLUSIONS: We identified five risk factors associated with the development of VTE despite thromboprophylaxis in the hospital setting. By recognizing these high-risk patients, clinicians can prescribe aggressive VTE prophylaxis judiciously and remain vigilant for signs or symptoms of VTE.
© 2013.

Entities:  

Keywords:  AHRQ PSI 12; Agency for Healthcare Research and Quality Patient Safety Indicators 12, version 4.2; Anticoagulation; CI; CVC; DVT; ICU; INR; MEDENOX trial; OR; PE; Risk factors; Thromboprophylaxis; VTE; Venous thromboembolism; central venous catheter; confidence interval; deep vein thrombosis; intensive care unit; international normalized ratio; odds ratio; pulmonary embolism; venous thromboembolism; “prophylaxis in medical patients with enoxaparin” trial

Mesh:

Substances:

Year:  2013        PMID: 24300584      PMCID: PMC4469358          DOI: 10.1016/j.thromres.2013.09.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  33 in total

1.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Authors:  Samuel Z Goldhaber; Alain Leizorovicz; Ajay K Kakkar; Sylvia K Haas; Geno Merli; Robert M Knabb; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.

Authors:  Francesco Dentali; James D Douketis; Monica Gianni; Wendy Lim; Mark A Crowther
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

4.  Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.

Authors:  Renée L Schiff; Susan R Kahn; Ian Shrier; Carla Strulovitch; Wahbi Hammouda; Eva Cohen; David Zukor
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

5.  Identification of residual risk factors for the development of venous thromboembolism in medical inpatients receiving subcutaneous heparin therapy for prophylaxis.

Authors:  Shumei Kato; Yuichi J Shimada; Patricia Friedmann; Glenn Kashan; Gregg Husk; Steven R Bergmann
Journal:  Coron Artery Dis       Date:  2012-06       Impact factor: 1.439

Review 6.  Venous thromboembolism in neurosurgery and neurology patients: a review.

Authors:  M G Hamilton; R D Hull; G F Pineo
Journal:  Neurosurgery       Date:  1994-02       Impact factor: 4.654

7.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

Review 8.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  Prevalence of deep venous thrombosis among patients in medical intensive care.

Authors:  D R Hirsch; E P Ingenito; S Z Goldhaber
Journal:  JAMA       Date:  1995-07-26       Impact factor: 56.272

10.  Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.

Authors:  Lisa J McGarry; Michael E Stokes; David Thompson
Journal:  Thromb J       Date:  2006-09-27
View more
  6 in total

1.  Pleural effusions as a predictive parameter for poor prognosis for patients with acute pulmonary thromboembolism.

Authors:  Xia Zhou; Zhu Zhang; Zhenguo Zhai; Yunxia Zhang; Ran Miao; Yuanhua Yang; Wanmu Xie; Jun Wan; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

2.  Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases.

Authors:  Adam S Faye; Timothy Wen; Ashwin N Ananthakrishnan; Simon Lichtiger; Gilaad G Kaplan; Alexander M Friedman; Garrett Lawlor; Jason D Wright; Frank J Attenello; William J Mack; Benjamin Lebwohl
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-20       Impact factor: 11.382

3.  Persistent neutrophilia is a marker for an increased risk of venous thrombosis.

Authors:  Margarita Kushnir; Hillel W Cohen; Henny H Billett
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

4.  Clinical characteristics and outcomes of venous thromboembolic events after hallux valgus surgery: insights from the RIETE registry.

Authors:  Bavand Bikdeli; Renuka Visvanathan; Ido Weinberg; Agustina Rivas; José Antonio Nieto; Ángel Sampériz; Mónica Loring; Fernando Javier Vázquez; Hugo Hyung Bok Yoo; Behnood Bikdeli; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

5.  [The incidence and risk factors of catheter-related-thrombosis during induction chemotherapy in acute lymphocytic leukemia children].

Authors:  Y Y Wei; Y Y Zhang; Y Z Zhen; L Q Zhang; C G Jia; R D Zhang; H Y Zheng; X Y Wu; R H Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

Review 6.  Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review.

Authors:  Francisco Galeano-Valle; Lucía Ordieres-Ortega; Crhistian Mario Oblitas; Jorge Del-Toro-Cervera; Luis Alvarez-Sala-Walther; Pablo Demelo-Rodríguez
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.